VivoSeq
0

Pipeline Programs

13

Active Trials

23

Companies Involved

TIA is an early-stage landscape with 0 programs across 23 companies. The most active players are GSK, AstraZeneca, Bayer.

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

7/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

140

clinical trials

Completed98 · 70%
Unknown status18 · 13%
Recruiting7 · 5%
Terminated6 · 4%
Withdrawn4 · 3%
Active, not recruiting4 · 3%
Other3 · 2%

Trial Activity

140 trials

Transient Receptor Potential Channels
Recruiting·PPenn State University·Phase 1·NCT06444594·45 enrolled
Assessing Optimal XRB Initiation Points in Jail
Recruiting·NNYU Langone Health·Phase 4·NCT06051890·200 enrolled
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Active, not recruiting··Phase 2·NCT03580928·72 enrolled
Facilitating Rapid Naltrexone Initiation
Active, not recruiting·NNew York State Psychiatric Institute·Phase 3·NCT03345173·100 enrolled
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
Not yet recruiting·JJohns Hopkins University·Phase 2/3·NCT07016321·600 enrolled
Levofloxacin Concomitant Versus Levofloxacin Sequential
Not yet recruiting··Phase 4·NCT06065267·150 enrolled
Study to Evaluate Potential Food Effects
Completed··Phase 1·NCT00791817·10 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)